CHDI Foundation extends collaboration with IRBM to develop Huntington’s disease therapeutics

IRBM has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a non-profit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD)

HD is a genetic neurodegenerative disease for which there are currently only very limited treatment options. The collaboration with CHDI demonstrates IRBM’s commitment and passion for developing novel therapeutic solutions for this devastating disease.

Since 2011, IRBM has worked closely with CHDI to investigate innovative therapeutic approaches based on a better understanding of the biology of the disease.

This has included significant contributions by IRBM to HD-specific mechanistic and translational research, as well as tailored drug discovery solutions.

The extension of this collaboration builds on IRBM’s expertise in the biology of neurodegenerative diseases, its comprehensive screening capabilities and continued access to IRBM’s compound collection and peptide libraries.

IRBM will also continue to leverage its significant experience in integrated neuroscience drug discovery with small molecules and biologics, including the development of clinically qualified diagnostic assays and the creation of predictive models for blood-brain barrier permeability.

Piero Di Lorenzo, President and founder of IRBM, said: “We are proud to be involved with this world-leading initiative to improve the quality of life of patients fighting against this terrible disease. Together with CHDI we are fully committed to help them: they deserve nothing less than our daily dedication.”

Robi Blumenstein, President of CHDI Management, Inc., said: “We are delighted to extend CHDI’s collaboration with our colleagues at IRBM. They have made invaluable contributions to a number of our programs and offer important services to the entire HD drug development community.”

Companies